entertainment -WSS

entertainment

author：knowledge 2025-10-01 23:02:09 - browse：588

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： FDA approves first blood sugar monitor without finger pricks

WSS

What PEPFAR has meant on the ground in Ukraine

Doctors have an ethical obligation to be advocates

My chronic pain journey would have been easier knowing 5 things % STAT

Where does female orgasm come from? Scientists think they know

Supreme Court wrestles with OxyContin maker's bankruptcy deal

SCOTUS to consider access to abortion pill mifepristone

Wikipedia

entertainment

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Activists slam private health insurers over coverage restrictions

The woman behind the Dana Farber

Medicare details structure of new drug price negotiation program

In diabetes hearing, Sanders takes on a new foe: food makers

Psychedelics group wrestles with new pharma identity

CMS should re

Peter Hotez and the public health issue of online harassment

Supreme Court wrestles with OxyContin maker's bankruptcy deal

focus

FDA needs staff influx to meet gene therapy needs, Marks says

The woman behind the Dana Farber

What PEPFAR has meant on the ground in Ukraine

Clinic falsely told dozens they had Alzheimer's, suits say

FDA approves first blood sugar monitor without finger pricks

How a key Senate committee is planning to regulate PBMs

leisure time

knowledge

hotspot

focus